Checkpoint inhibitor-based immunotherapy (CPI) has ushered in a new era in cancer treatment. CPI has shown promising outcomes in clinical studies, particularly in treating melanoma, non-small cell lung cancer, and a number of other cancers. However, CPI, currently using antibodies to CTLA-4, PD-1, and PD-L1, also has limitations. In most cases CPI can only be effective in a small percentage of patients of a given cancer. The major obstacles include initial resistance, refraction after initial response, high cost, and potential autoimmune side effects (particularly with high dose of checkpoint inhibitors). Biophotonics-based immunotherapy (BPI) uses a combination of phototherapy and immunostimulant, often through a local intervention. BPI has shown a great potential in inducing systemic, tumor-specific immunity against the target tumor. It has been used to treat metastatic cancers with promising outcomes. We anticipate that BPI can synergize with CPI by providing the quality and
|